Various VEGF signal inhibitors, including anti-VEGF neutralizing antibodies and VEGFR kinase/multi-kinase inhibitors, have been successfully developed and are now widely used in the clinic, particularly for colorectal cancer, lung cancer, breast cancer, glioblastoma, liver cancer and renal cell carcinoma treatment [38-40]. The gene discussed is VEGFA; the disease is breast cancer.